# Indian Immunologicals unveils paediatric dose of indigenous hepatitis A vaccine, Havisure

05 September 2024 | News

Vaccination is the most cost effective yet efficient method to prevent hepatitis

Hyderabad-based Indian Immunologicals Limited (IIL) has announced the launch of its latest breakthrough- the paediatric dose of India's first indigenous Hepatitis A vaccine, Havisure (0.5 ml).

This launch marks a significant milestone in IIL's ongoing commitment to providing affordable and effective vaccines for all, especially for the most vulnerable sections of society, particularly children.

Hepatitis A is a highly contagious liver infection caused by the Hepatitis A virus, which predominantly affects children and can lead to severe health complications. Vaccination is the most cost effective yet efficient method to prevent the disease.

Addressing on the occasion, Dr K. Anand Kumar, Managing Director of Indian Immunologicals Limited, said, "We are delighted to introduce the paediatric dose of Havisure, the first indigenously developed Hepatitis A vaccine in India. IIL is the single largest contributor to the self-sufficiency of vaccines in the country, this launch is a testament to IIL's unwavering dedication to innovation and public health."

In line with its commitment to public health and social responsibility, IIL marked this significant launch with a series of community-focused activities. IIL organised free Hepatitis A vaccination drives for children in two orphanages in Hyderabad to start with, which includes one specifically for blind children. IIL also conducted a health awareness session at an old age home, and these are continuous efforts towards creating awareness and better health for the community at large.

The launch of Havisure reinforces IIL's long-standing commitment to innovation and public health, solidifying its position as the only company in India to develop an indigenous Hepatitis A vaccine, available in both 0.5 ml and 1 ml dosage forms for paediatric and adult use, respectively.